NZX/ASX Announcement

13 January 2025

TruScreen invited to present at WHO global AI collaboration meeting

- **TruScreen presented to a World Health Organisation (WHO) global meeting to further the use of AI technologies for screening of cervical cancer**
- **The presentation by CEO, Marty Dillon is attached for the information of stakeholders**

At the invitation of World Health Organisation (WHO) TruScreen Group Limited (NZX/ASX:TRU) presented at a WHO global AI collaboration meeting on 11 and 12 November 2024 in Edinburgh. The meeting investigated the further use of Artificial Intelligence (AI) technologies for cervical cancer screening.

TruScreen's unique AI enabled technology was the only opto-electric tissue differentiating medical device company invited to participate.

This invitation followed on from the UNITAID Report that featured TruScreen as a technology, currently in commercial use, for the primary screening of cervical cancer. After years of clinical trials, TruScreen technology received recent recognition by peak Medical Organisations and national Government agencies including:

- the Chinese Obstetricians and Gynaecologists Association (COGA),
- the Chinese Society for Colposcopy and Cervical Pathology (CSCCP),
- the Vietnam Ministry of Health National Technical List,
- COFEPRIS, the Mexican public health regulator, and
- The Russia Cervical Cancer Screening Guidelines.

TruScreen Chair, Mr Tony Ho commented:

"This WHO invitation was significant for TruScreen, and signals that, along with the recent recognition by national government agencies and peak Medical Organisations, that WHO recognises the use of TruScreen's unique AI enabled opto-electric technology to reduce the preventable deaths of women from cervical cancer.

This is particularly relevant in TruScreen's target markets – countries with limited or no cervical cancer screening programs, that resulted in high cervical cancer mortality rates. Ninety percent (90%) of cervical cancer deaths worldwide occur in these countries."

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Martin Dillon

Chief Executive Officer

martindillon@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors

In financial year 2024 alone, over 200,000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"©.

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

Glossary:

Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity* and *specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, conditioned on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative (Sensitivity and specificity – Wikipedia).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council